YU7998A - Heterociklična jedinjenja i njihove farmaceutske kompozicije - Google Patents

Heterociklična jedinjenja i njihove farmaceutske kompozicije

Info

Publication number
YU7998A
YU7998A YU7998A YU7998A YU7998A YU 7998 A YU7998 A YU 7998A YU 7998 A YU7998 A YU 7998A YU 7998 A YU7998 A YU 7998A YU 7998 A YU7998 A YU 7998A
Authority
YU
Yugoslavia
Prior art keywords
heterocyclic compounds
pharmaceutic compositions
tiazoline
amiloid
etil
Prior art date
Application number
YU7998A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Eugene D. Thorsett
Warren J. Porter
Jeffrey S. Nissen
Lee H. Latimer
James E. Audia
James Droste
Original Assignee
Athena Neurosciences Inc.
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc., Eli Lilly And Company filed Critical Athena Neurosciences Inc.
Publication of YU7998A publication Critical patent/YU7998A/sh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
YU7998A 1997-02-28 1998-02-27 Heterociklična jedinjenja i njihove farmaceutske kompozicije YU7998A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80826397A 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
YU7998A true YU7998A (sh) 2002-06-19

Family

ID=25198310

Family Applications (1)

Application Number Title Priority Date Filing Date
YU7998A YU7998A (sh) 1997-02-28 1998-02-27 Heterociklična jedinjenja i njihove farmaceutske kompozicije

Country Status (22)

Country Link
EP (1) EP0968198A1 (id)
JP (1) JP2001513107A (id)
KR (1) KR20000075767A (id)
CN (1) CN1253554A (id)
AR (1) AR011164A1 (id)
AU (1) AU6662298A (id)
BR (1) BR9807876A (id)
CA (1) CA2278674A1 (id)
CO (1) CO4920244A1 (id)
EA (1) EA199900778A1 (id)
HR (1) HRP980093A2 (id)
HU (1) HUP0001293A3 (id)
ID (1) ID22873A (id)
IL (1) IL130851A0 (id)
NO (1) NO994016L (id)
NZ (1) NZ336613A (id)
PE (1) PE59399A1 (id)
PL (1) PL335424A1 (id)
TR (1) TR199902071T2 (id)
WO (1) WO1998038177A1 (id)
YU (1) YU7998A (id)
ZA (1) ZA981627B (id)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
IL135564A0 (en) * 1997-12-22 2001-05-20 Elan Pharm Inc POLYCYCLIC α-AMINO-ɛ-CAPROLACTAMS AND RELATED COMPOUNDS
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911803D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
WO2001092235A1 (en) 2000-06-01 2001-12-06 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
DE10029077A1 (de) * 2000-06-13 2001-12-20 Bayer Ag Thiazolylsubstituierte Heterocyclen
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2840899B1 (fr) * 2002-06-12 2005-02-25 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
CA2486350A1 (en) 2002-06-05 2003-12-24 Kaneka Corporation Process for producing optically active .alpha.-methylcysteine derivative
NZ584773A (en) 2004-09-17 2012-07-27 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2008042928A2 (en) 2006-10-03 2008-04-10 Array Biopharma, Inc. Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
WO2010006792A1 (de) * 2008-07-16 2010-01-21 Bitop Ag Synthese von zyklischen amidinen
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN103435549A (zh) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法
CN105646208B (zh) * 2016-02-24 2018-10-16 潍坊晶润化工股份有限公司 丙酮酸甲酯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831920A4 (en) * 1995-06-06 2003-03-19 Athena Neurosciences Inc NOVEL CATHEPSIN AND METHODS AND COMPOSITIONS FOR INHIBITING CATHEPSIN

Also Published As

Publication number Publication date
NZ336613A (en) 2001-10-26
HRP980093A2 (en) 1998-12-31
TR199902071T2 (xx) 2000-01-21
EA199900778A1 (ru) 2000-04-24
HUP0001293A3 (en) 2000-09-28
BR9807876A (pt) 2000-02-29
CO4920244A1 (es) 2000-05-29
EP0968198A1 (en) 2000-01-05
CN1253554A (zh) 2000-05-17
ID22873A (id) 1999-12-16
HUP0001293A1 (hu) 2000-08-28
ZA981627B (en) 1999-10-05
KR20000075767A (ko) 2000-12-26
WO1998038177A1 (en) 1998-09-03
PL335424A1 (en) 2000-04-25
NO994016D0 (no) 1999-08-19
IL130851A0 (en) 2001-01-28
CA2278674A1 (en) 1998-09-03
AU6662298A (en) 1998-09-18
JP2001513107A (ja) 2001-08-28
PE59399A1 (es) 1999-06-21
NO994016L (no) 1999-10-18
AR011164A1 (es) 2000-08-02

Similar Documents

Publication Publication Date Title
YU7998A (sh) Heterociklična jedinjenja i njihove farmaceutske kompozicije
IL108943A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DE69326250D1 (de) Neuropeptide y antagoniste
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
PT741716E (pt) Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem
AR017219A1 (es) Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
IL106777A (en) Monohydrate of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6- chloro-1, 3-dihydro-2h- indole-2-one hydrochloride and pharmaceutical compositions comprising it
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
TR199901653T2 (xx) Fitalazinonlar.
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
HUP9603237A3 (en) Crystalline hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxydo-3-oxo-2,3-dihydro-benzisothiazo-2-yl)-butyl]-amino-methyl}-chromane, process for the preparation thereof and pharmaceutical compositions containing them
IL105989A (en) N-substituted azabicycloheptane derivatives and pharmaceutical compositions containing them
MY120156A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
NO971997D0 (no) Bruk av immunmodulerende midler
DE59108566D1 (de) Heteroarylmethylbenzole-Aromatasehemmer
ATE141248T1 (de) Neue bis-phenyl-hexene
NO972435L (no) 2-(2,3,5,6-tetrafluor-4-pyridyl)-1,2,5-tradiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
IL85640A0 (en) 1-(1-aryl-2-hydroxyethyl)-imidazoles and salts thereof,processes for the preparation thereof and pharmaceutical compositions containing them
NO972450L (no) Substituerte 2-(fosfinyloksymetyl)-1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metode for anvendelse derav
HUP9801761A3 (en) Fumarate salt of (r)-5-(methylaminosulphonyl-methyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole, preparation and use thereof and pharmaceutical composition containing this compound
IL114239A0 (en) Pyrrolidine derivatives their preparation and com¦ositions containing them